SAN DIEGO, April 23, 2014 -- Fate Therapeutics, Inc. , a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced today that the U.S. Food and Drug Administration has cleared its Investigational New Drug Application amendment to evaluate PROHEMA in pediatric patients ... (more)
http://ift.tt/1jL9reL
http://ift.tt/1jL9reL
No comments:
Post a Comment